Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT01045928
What this trial is testing

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Adult Non-Hodgkin LymphomaAdult Grade III Lymphomatoid GranulomatosisContiguous Stage II Adult Burkitt Lymphoma+77 more
Case Comprehensive Cancer Center 5
Early research (Phase 1)Study completedNCT02504359
What this trial is testing

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Who this might be right for
Plasma Cell LeukemiaRecurrent Plasma Cell Myeloma
OHSU Knight Cancer Institute 11
Testing effectiveness (Phase 2)Ended earlyNCT02756728
What this trial is testing

A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma

Who this might be right for
Multiple Myeloma
BioInvent International AB 5
Large-scale testing (Phase 3)Study completedNCT00398411
What this trial is testing

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

Who this might be right for
Hodgkin DiseaseNon-Hodgkin LymphomaMultiple Myeloma+1 more
University of Cologne 66
Early research (Phase 1)Study completedNCT03042793
What this trial is testing

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Who this might be right for
Multiple Myeloma
Lene Meldgaard Knudsen 10
Large-scale testing (Phase 3)Study completedNCT01091831
What this trial is testing

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 389
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07600151
What this trial is testing

Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
Myeloma MultipleMyeloma
Universitätsklinikum Hamburg-Eppendorf 220
Not applicableStudy completedNCT00577096
What this trial is testing

Effects of Exercise in Combination With Epoetin Alfa

Who this might be right for
Multiple Myeloma
University of Arkansas 120
Testing effectiveness (Phase 2)Study completedNCT00790647
What this trial is testing

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Who this might be right for
Multiple Myeloma
Boston Medical Center 10
Testing effectiveness (Phase 2)Study completedNCT00002630
What this trial is testing

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 50
Early research (Phase 1)Looking for participantsNCT06544265
What this trial is testing

SynKIR-310 for Relapsed/Refractory B-NHL

Who this might be right for
B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more
Verismo Therapeutics 36
Testing effectiveness (Phase 2)Study completedNCT01302886
What this trial is testing

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Novartis Pharmaceuticals 41
Testing effectiveness (Phase 2)Looking for participantsNCT06948084
What this trial is testing

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
National Cancer Institute (NCI) 80
Testing effectiveness (Phase 2)Study completedNCT00577512
What this trial is testing

2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE

Who this might be right for
Multiple Myeloma
University of Arkansas 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04653246
What this trial is testing

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Who this might be right for
Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Autologous Stem Cell Transplant
Jacob Laubach, MD 52
Not applicableEnrolling By InvitationNCT03689595
What this trial is testing

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 30,000
Testing effectiveness (Phase 2)UnknownNCT03641456
What this trial is testing

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Who this might be right for
MyelomaNewly DiagnosedHigh Risk
Sun Yat-sen University 50
Early research (Phase 1)Ended earlyNCT00725062
What this trial is testing

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Masonic Cancer Center, University of Minnesota 3
Testing effectiveness (Phase 2)Ended earlyNCT04816526
What this trial is testing

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Who this might be right for
Myeloma Multiple
Cartesian Therapeutics 13
Not applicableStudy completedNCT02716103
What this trial is testing

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 45
Next Page